Clinical trial
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
NCT00003871 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003871 |
|---|---|
| Title | PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer |
| Official title | Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine |
| Enrollment | 60 |
| Start date | Sep 24, 1999 |
| Primary completion | Jun 1, 2002 |
| First posted | Jun 16, 2004 |
| Last update posted | Jun 22, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: